Get the Stockscreener App
41.62
2.67%
-1.14
Pre-market:
41.80
0.18
+0.43%
Xenon Pharmaceuticals Inc stock is traded at $41.62, with a volume of 718.33K.
It is down -2.67% in the last 24 hours and up +0.95% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$42.76
Open:
$42.89
24h Volume:
718.33K
Relative Volume:
0.85
Market Cap:
$3.22B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-15.19
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+3.05%
1M Performance:
+0.95%
6M Performance:
+15.64%
1Y Performance:
+5.37%
1-Day Range:
$41.50
$43.00
1-Week Range:
$40.74
$43.66
52-Week Range:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
41.62 | 3.30B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews
Xenon Pharmaceuticals Inc. (XENE) Investor Outlook: Strong Buy Ratings and 31.57% Potential Upside - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (XENE) Movement - Stock Traders Daily
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - Defense World
Published on: 2026-02-04 12:37:47 - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: A Biotech Gem with 33.91% Upside Potential - DirectorsTalk Interviews
Published on: 2026-02-02 18:11:01 - baoquankhu1.vn
Published on: 2026-01-30 01:17:54 - mfd.ru
J. Safra Sarasin Holding AG Sells 51,880 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Market Catalysts: Is Xenon Pharmaceuticals Inc forming a bullish divergence2025 Winners & Losers & Technical Pattern Alert System - baoquankhu1.vn
Rate Hike: What is the Moat Score of WETHWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Action: Does Xenon Pharmaceuticals Inc stock have upside surprise potentialWeekly Loss Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon (XENE) Receives a Buy from J.P. Morgan - The Globe and Mail
Published on: 2026-01-20 17:07:34 - baoquankhu1.vn
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: A 38.87% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ten new Xenon hires receive 42,300 stock options vesting over 4 years - Stock Titan
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Trend Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: Biotechnology Innovator with a 34% Upside Potential - DirectorsTalk Interviews
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - The Globe and Mail
New seizure and depression drug faces key 2026 test in late-stage trials - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $62.00 at JPMorgan Chase & Co. - Defense World
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
JPMorgan Chase & Co. Increases Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $62.00 - MarketBeat
JPMorgan reiterates Overweight rating on Xenon Pharmaceuticals stock By Investing.com - Investing.com UK
XENE: JP Morgan Raises Xenon Pharmaceuticals' Price Target | XEN - GuruFocus
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Is Xenon Pharmaceuticals Inc. stock supported by strong cash flowsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Can Xenon Pharmaceuticals Inc. stock maintain operating marginsQuarterly Trade Review & Stepwise Trade Execution Plans - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockLong-Term Growth Stocks & We Spotted the Next Tesla – See Inside - Улправда
Why Xenon Pharmaceuticals Inc. stock remains undervaluedForecast Cut & Free Reliable Trade Execution Plans - ulpravda.ru
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - TechStock²
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):